Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort
- 188 Downloads
Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France.
We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied.
During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed.
Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.
KeywordsDrug utilisation study Psychotropic drugs Antidepressant drugs Pregnancy
This study is part of the Drugs Systematized Assessment in real-liFe Environment (DRUGS-SAFE) research program funded by the French Medicines Agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé, ANSM). This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency. EFEMERIS database is funded by the ANSM, the Caisse Nationale d’Assurance Maladie des travailleurs salariés (CNAMTS) and the Clinical Research Hospital Program (PHRC).
Compliance with ethical standards
Conflict of interest
Caroline Hurault-Delarue, Isabelle Lacroix, Anne Bénard-Laribière, Jean-Louis Montastruc, Antoine Pariente and Christine Damase-Michel declare that they have no conflict of interest with the Pharmaceutical Industry.
The EFEMERIS database was approved by the French Data Protection Agency (Commission Nationale de l’Informatique et des Libertés, CNIL) on 7 April 2005 (authorisation number 05-1140). Women were informed of the study and could refuse to participate. In accordance with French regulations, ethics committee approval was not required for this observational study conducted on anonymous medico-administrative data.
- 1.Bennett HA, Einarson A, Taddio A et al (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709. https://doi.org/10.1097/01.AOG.0000116689.75396.5f CrossRefGoogle Scholar
- 2.Gavin NI, Gaynes BN, Lohr KN et al (2005) Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 106:1071–1083. https://doi.org/10.1097/01.AOG.0000183597.31630.db CrossRefGoogle Scholar
- 3.Jimenez-Solem E (2014) Exposure to antidepressants during pregnancy—prevalences and outcomes. Dan Med J 61:B4916Google Scholar
- 9.Oberlander TF, Warburton W, Misri S et al (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906. https://doi.org/10.1001/archpsyc.63.8.898 CrossRefGoogle Scholar
- 19.WHOCC ATC classification. https://www.whocc.no/atc_ddd_index/?code=N06A&showdescription=no. Accessed 23 Mar 2017
- 21.Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544.e1–544.e5. https://doi.org/10.1016/j.ajog.2007.01.033
- 24.Andrade SE, Raebel MA, Brown J et al (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–194.e5. https://doi.org/10.1016/j.ajog.2007.07.036
- 25.ANSM (2006) Modification de la rubrique grossesse du Résumé des Caractéristiques du Produit (RCP) de Deroxat® (chlorhydrate de paroxétine hémihydraté)—ANSM: Agence nationale de sécurité du médicament et des produits de santé. http://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Modification-de-la-rubrique-grossesse-du-Resume-des-Caracteristiques-du-Produit-RCP-de-Deroxat-R-chlorhydrate-de-paroxetine-hemihydrate. Accessed 20 Dec 2016
- 26.ANSM (2005) Paroxetine* et risque de malformation congénitale: points d’étape sur les résultats de l’évaluation européenne—ANSM : Agence nationale de sécurité du médicament et des produits de santé. http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Paroxetine-et-risque-de-malformation-congenitale-points-d-etape-sur-les-resultats-de-l-evaluation-europeenne. Accessed 20 Dec 2016
- 27.FDA (2006) Postmarket drug safety information for patients and providers—public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124348.htm. Accessed 24 Mar 2017
- 28.FDA (2005) Postmarket drug safety information for patients and providers—public health advisory: paroxetine. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm. Accessed 24 Mar 2017
- 38.INSEE (2016) Les naissances en 2015. https://www.insee.fr/fr/statistiques/2106549?sommaire=2106619. Accessed 20 Dec 2016